Diamedica Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Diamedica Therapeutics Inc 's ROA in the second quarter of 2026?
Diamedica Therapeutics Inc recorded a cumulative net loss of $-38 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -59%.

However, within the Healthcare sector 660 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4115, from total ROA ranking in the first quarter of 2026 at 4795.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	167.74 %	33.7 %	32.8 %	8.81 %	-44.7 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-38	-35	-33	-32	-30
Return On Assets (TTM)	-59 %	-69.46 %	-69.42 %	-73.52 %	-69.97 %
DMAC's Total Ranking	# 4115	# 4795	# 4226	# 4270	# 4220
Total Assets (TTM) in million	84	53	61	57	31
Seq. Total Assets Change	58.06 %	-13.52 %	7.65 %	81.96 %	-21.08 %
Seq. Net Income Change	-	-	-	-	-

DMAC's 5 Years Annual ROA >> Back to DMAC Management Effectiveness >> Compare DMAC ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 301
Sector	# 661
Overall	# 4080

Return On Assets Statistics
High	Average	Low
-30.88 %	-53.01 %	-88.04 %
(Jun 30 2022)		(Dec 31 2019)

News about Diamedica Therapeutics Inc Return on Assets ROA

Embarking on New Frontiers in Maternal Healthcare The Quest of DiaMedica Therapeutics in Preeclampsia Treatment with ...

Innovative Pursuits in Preeclampsia Treatment: DiaMedica Therapeutics Embarks on Phase 2 Trial of DM199 In the pursuit of advanced therapeutic interventions for preeclampsia (PE), a formidable condition prevalent in obstetric medicine, DiaMedica Therapeutics Inc. has embarked on a significant clinical investigation by dosing the first patient in an investigator-sponsored Phase 2 trial of their novel pharmaceutical compound, DM199. This pioneering endeavour represents a pivotal moment in the company’s quest to ameliorate severe ischemic conditions, specifically through the exploration of DM199 s efficacy in addressing the complexities of PE.The trial, which is conducted under the auspices of DiaMedica Therapeutics a clinical-stage biopharmaceutical entity listed on the Nasdaq stock exchange under the ticker DMAC aims to delineate the potential therapeutic impact of DM199, a promising treatment candidate. DiaMedica anticipates unveiling the initial proof-of-concept data, referred to as top-line data, for Part 1A of the study in the first half of 2025. This forthcoming data is poised to elucidate whether DM199 can substantiate its therapeutic promise amidst a backdrop of existing medical paradigms.

Innovation in Preeclampsia Treatment DiaMedica Therapeutics Gains Regulatory Approval for Phase 2 Clinical Trial of D...

Preeclampsia, a complex hypertensive disorder occurring during pregnancy, poses significant risks to maternal and fetal health. New therapeutic strategies to address this condition are urgently needed. DiaMedica Therapeutics Inc. a clinical-stage biopharmaceutical company focused on severe ischemic diseases, has recently received regulatory approval from the South African Health Products Regulatory Authority (SAHPRA) to commence a Phase 2 clinical trial for DM199. This study will explore the potential of this recombinant serine protease as a new treatment for preeclampsia. This article provides an overview of DM199, the implications of the regulatory approval, and the progress and strategic s of DiaMedica Therapeutics. Preeclampsia remains a leading cause of maternal and fetal morbidity and mortality worldwide. Characterized by high blood pressure and damage to organs, most often the liver and kidneys, it requires innovative treatment solutions. Current therapeutic approaches are limited, and often invasive, necessitating early delivery with risks for premature birth. DiaMedica Therapeutics Inc. is spearheading potential innovation in this field with the development of DM199, a novel approach harnessing the therapeutic action of a recombinant enzyme.

Financial Statements
Diamedica Therapeutics Inc 's Assets	$ 84 million	DMAC's Balance sheet
Diamedica Therapeutics Inc 's Income	$ -10 million	Quarterly DMAC's Income Statement
DMAC's Income by Division		See DMAC's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	32.8 %	-14.39 %	58.39 %	-25.35 %	62.56 %
Total Assets in million	61	46	54	34	46
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-33	-24	-19	-14	-14
Annual Return On Assets	-53.56 %	-53.06 %	-36.02 %	-40.26 %	-29.87 %

DMAC's 5 Years Annual ROA >> Back to DMAC Management Effectiveness >> Compare DMAC ROA to its Competitors

More Return On Assets Ratios
DMAC's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
DMAC's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for DMAC's Competitors
Subscribers only: Roa for Diamedica Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for DMAC's Customers

You may also want to know
DMAC's Roi	DMAC's Inventory Turnover Ratio	DMAC's Growth Rates	DMAC's Dividend Comparisons
	DMAC's Profitability Ratios	DMAC's Asset Turnover Ratio	DMAC's Dividend Growth
DMAC's Roe	DMAC's Valuation Ratios	DMAC's Financial Strength Ratios	DMAC's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-08-14T05:17:36+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.